Prevalence, consequences and data management (EPI) unit
This unit builds upon and rationalises existing working practices within the EMCDDA. The unit is responsible for the collection of the bulk of the agency’s epidemiological data and its analysis and reporting. The focus of the work is the development of common tools to describe the drug situation and understand the impact of different patterns of use on morbidity and mortality. The unit is also the base for the statistical support and data management team, which serves a transversal role in ensuring appropriate processing of all data sets held by the EMCDDA including but not restricted to the epidemiological key indicators.
Mission statement: To analyse and to ensure improved comparability, objectivity and reliability of existing data on the drug situation.
The unit’s principal aims are:
| Prevalence, consequences and data management (EPI) unit | |
|---|---|
| Head of unit | Julian Vicente |
| Administrative assistant | Sofia Cabral |
| Principal scientist infectious diseases and modelling | Lucas Wiessing |
| Principal scientific analyst prevalence and trends* | Deborah Olszewski |
| Senior scientific analyst service utilisation and needs | Linda Montanari |
| Scientific analyst int. and problem drug use and polydrug use | Danica Thanki |
| Scientific analyst health consequences* | Isabelle Giraudon |
| Data management and statistical support team | |
| Head of team | André Noor |
| Scientific support officer | Luís Royuela |
| Scientific assistant | Bruno Guarita |
| Scientific assistant | João Matias |
| Scientific assistant | Eleni Kalamara |
Note: e-mail addresses have been inserted in a way discouraging spam. Please replace [a] by @ before actually using any of the e-mail addresses.
* Shared assignment with SAT unit from February to December 2013
